The Cancer Center Director has the responsibility and authority to set priorities and to develop new programs for the Cancer Center. Faculty and senior leadership are the primary drivers in developing the focus of new research areas. External consultants and seminar speakers provide new perspectives on emerging areas of research and provide useful advice for possible future research directions. The Cancer Center leadership and several internal advisory groups serve to develop a specific set of goals from identified opportunities and available resources. The External Scientific Advisory Committee (EXSAC) meets each spring to review existing programs and proposed recruitment and scientific targets that have been developed by the senior leadership and faculty. These discussions inform the recruitment targets and planning efforts that begin each fall. Once new research goals are set, faculty are encouraged to pursue and support these goals through incentives that include pilot project funding, research instrumentation purchases, development of shared facilities, and recruitment of new faculty who are potential collaborators. Identification of shared facility and common equipment needs originates with the investigators and their laboratory staff, and is integrated at the level of the Internal Steering and Shared Resources Committees. Program members serving on recruitment committees identify and recommend the selection of new faculty, who bring to the Cancer Center new research areas, technologies, and opportunities for collaboration. The main internal advisory bodies include: i) the Cancer Center Executive Committee, ii) the Internal Steering Committee, iii) the Membership Committee and iv) the Shared Resources Committee. The External Scientific Advisory Committee (EXSAC) currently has 10 members representative of a broad spectrum of cancer research. Funding in the amount of $10,000 is requested for the annual meeting of the EXSAC;$5,000 is requested for the annual Cancer Center member retreat, and $6,000 is requested for planning and evaluation meetings for the Scientific Program groups.
| Schug, Zachary T (2018) Formaldehyde Detoxification Creates a New Wheel for the Folate-Driven One-Carbon ""Bi""-cycle. Biochemistry 57:889-890 |
| Karakashev, Sergey; Zhu, Hengrui; Wu, Shuai et al. (2018) CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity. Nat Commun 9:631 |
| Jenkins, Russell W; Aref, Amir R; Lizotte, Patrick H et al. (2018) Ex Vivo Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids. Cancer Discov 8:196-215 |
| Barnoud, Thibaut; Budina-Kolomets, Anna; Basu, Subhasree et al. (2018) Tailoring Chemotherapy for the African-Centric S47 Variant of TP53. Cancer Res 78:5694-5705 |
| Barbieri, Elisa; Trizzino, Marco; Welsh, Sarah Ann et al. (2018) Targeted Enhancer Activation by a Subunit of the Integrator Complex. Mol Cell 71:103-116.e7 |
| Seo, Jae Ho; Agarwal, Ekta; Bryant, Kelly G et al. (2018) Syntaphilin Ubiquitination Regulates Mitochondrial Dynamics and Tumor Cell Movements. Cancer Res 78:4215-4228 |
| Lu, Huimin; Bowler, Nicholas; Harshyne, Larry A et al. (2018) Exosomal ?v?6 integrin is required for monocyte M2 polarization in prostate cancer. Matrix Biol 70:20-35 |
| Stout, Matthew C; Narayan, Shilpa; Pillet, Emily S et al. (2018) Inhibition of CX3CR1 reduces cell motility and viability in pancreatic adenocarcinoma epithelial cells. Biochem Biophys Res Commun 495:2264-2269 |
| Hu, Xiaowen; Sood, Anil K; Dang, Chi V et al. (2018) The role of long noncoding RNAs in cancer: the dark matter matters. Curr Opin Genet Dev 48:8-15 |
| Saglam, Ozlen; Conejo-Garcia, Jose (2018) PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer. Integr Cancer Sci Ther 5: |
Showing the most recent 10 out of 741 publications
